Published in Vaccine Weekly, February 10th, 1997
As a result of this decision and national patent legislation that has already passed in select European countries, Biogen expects that its entire European hepatitis B patent portfolio will be extended for an additional one to five years from the original expiration dates, depending on the market.
Jim Vincent, Biogen, said, "We are very pleased by this important decision, which ensures that Biogen will continue to receive all of its current...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.